Se confirma...GLAXO compra Genoma.$3.00 billion

The rumours were right and GlaxoSmithKline has won the day to acquire Human Genome Sciences, raising its original offer by $1.25 to $14.25 per share.

The transaction values HGS at $3.60 billion on an equity basis, or $3.00 billion net of cash and debt, and represents a premium of 99% to the HGS closing price of $7.17 per share on April 18. That was the last day of trading before HGS publicly disclosed GSK’s initial private offer of $13 per share, or $2.60 billion, which was repeatedly rejected by the US biotech's board.

Más